Use of the glutoxim drug in the complex treatment of combined infection of tuberculosis and new coronavirus infection
https://doi.org/10.34680/2076-8052.2024.4(138).618-624
Abstract
The article discusses the problem of combined infection of tuberculosis and new coronavirus infection during the pandemic. The search for effective means for the treatment of patients with tuberculosis and new coronavirus infection, as well as the prevention of complications of these diseases is a priority for phthisiologists and infectious disease specialists. The class of regulators of the body's internal defense systems, according to their pharmacological activity, belong to antibiotic adjuvants. A representative of this class is the domestic Glutoxim drug. The main pharmacological effects of this drug are the antimicrobial therapy enhancement, including increasing the availability of the microorganism (pathogen) to the action of drugs and, subsequently, overcoming the drug resistance of microorganisms, as well as eliminating the imbalance of redox homeostasis. The article shows the effectiveness of Glutoxim in the treatment of patients with tuberculosis and new coronavirus infection.
About the Authors
A. V. Karpov
Yaroslav-the-Wise Novgorod State University; Novgorod Clinical Specialized Center for Phthisiopulmonology
Russian Federation
Russian Federation
Veliky Novgorod
P. A. Gudz
Yaroslav-the-Wise Novgorod State University; Novgorod Clinical Specialized Center for Phthisiopulmonology
Russian Federation
Russian Federation
Veliky Novgorod
E. D. Trufanova
Yaroslav-the-Wise Novgorod State University
Russian Federation
Russian Federation
Veliky Novgorod
References
1. Jarman O. Otsenka retsidivov tuberkuleza v usloviyakh novoy koronavirusnoy infektsii [Evaluation of tuberculosis relapses in the context of a new coronavirus infection] // Medicine and health care organization. 2023. 8 (1). 71-81. DOI: 10.56871/MHCO.2023.86.49.007
2. Komissarova O. G., Abdullaev R. Yu., Shorokhova V. A. Osobennosti tuberkuleza legkikh u bol'nykh, perenesshikh infektsiyu, vyzvannuyu SARS-COV-2 [Features of lung tuberculosis in patients who have had an infection caused by SARS-CoV-2] // Modern problems of science and education. 2023. 4. 90. DOI: 10.17513/spno.32737
3. Lebedeva I. B., Osintseva I. Yu., Bondarenko T. E., Pyanzova T. V., Brusina E. B. COVID-19 v populyatsii bol'nykh tuberkulezom: epidemiologicheskaya i klinicheskaya kharakteristika [COVID-19 in patients with tuberculosis: epidemiological and clinical features] // Fundamental and Clinical Medicine. 2021. 6 (3). 71-84. DOI: 10.23946/2500-0764-2021-6-3-71-84
4. Baitelieva A. K., Chubakov T. Ch. Latentnaya tuberkuleznaya infektsiya i koronavirusnaya infektsiya [Latent tuberculosis infection and coronavirus infection] // Scientific review. Medical sciences. Biological series. 2021. 5. 12-18. DOI: 10.17513/srms.1204
5. But P. G., Muravyov R. A., Fomina V. A. Vnutrikletochnoye preobrazovaniye fagosom [Intracellular transformation of phagosomes] // Bulletin of the Russian Academy of Sciences. 2004. 6. 678-681.
6. Nikitina O. A. Aktivnost' reaktsiy lipoperoksidatsii-antioksidantnoy zashchity u bol'nykh s VICH-infektsiyey (obzor) [Activity of lipoperoxidation - antioxidant protection reactions in patients with HIV infection (review)] // Acta biomedical scientifica. 2020. 5 (6). 124-132. DOI: 10.29413/ABS.2020-5.6.14
7. Zhirnova M. Yu., Lvov S. L., Anisimova T. A. Tuberkulez i COVID-19: problemy diagnostiki i osobennosti vedeniya patsiyentov v usloviyakh pandemii [Tuberculosis and COVID-19: diagnostic problems and features of patient management in a pandemic] // StudNet: scientific and educational journal for students and teachers. 2022. 5 (5). 148.
8. German A. A., Boyko A. V. Sposob lecheniya mul'tirezistentnogo tuberkuleza [Method for treating multidrug-resistant tuberculosis] // Bulletin of Medical Internet Conferences (ISSN 2224-6150). 2012. 2 (11). 954.
9. Bogush T. A., Dudko E. A., Bogush E. A., Kirsanov V. Yu., Antonov V. G. Glutoksim kak ingibitor fenotipa mnozhestvennoy lekarstvennoy rezistentnosti, assotsiirovannoy s ekspressiyey Pgp [Glutoxime, as an inhibitor of multiple drug resistance phenotype associated with Pgp expression] // Antibiotics and Chemotherapy. 2010. 55 (5-6).18-23.
10. Manicheva O. A., Solovieva N. S., Antonov V. G., Zhuravlev V. Yu., Mazokhina S. V., Zmaznova A. E. Vliyaniye Glutoksima na antimikobakterial'nuyu aktivnost' izoniazida v otnoshenii lekarstvenno-ustoychivykh shtammov Mycobacteriumtuberculosis [Effect of Glutoxim on the antimycobacterial activity of isoniazid against drug-resistant strains of Mycobacterium tuberculosis] // Tuberculosis and Lung Diseases. 2014. 9. 89-96. DOI: 10.21292/2075-1230-2014-0-9-20-25
Review
For citations:
Karpov A.V., Gudz P.A., Trufanova E.D. Use of the glutoxim drug in the complex treatment of combined infection of tuberculosis and new coronavirus infection. Title in english. 2024;(4(138)):618-624. (In Russ.) https://doi.org/10.34680/2076-8052.2024.4(138).618-624
Views:
13
Email this article 